ABSTRACT
Objective To explore the expression of microRNA506 in brain tissue of mice with cere-bral ischemia reperfusion injury and its effect on proliferation and apoptosis of SH-SY5Y cells. Method-s Middle cerebral artery occlusion(MCAO)was used to establish the model of cerebral ischemia reperfu-sion in mice,and RT-PCR(reverse transcription polymerase chain reaction)was used to detect the expres-sion level of microRNA506 in the brain tissue of mice. MicroRNA506 overexpression plasmids and interfer-ence plasmids were constructed and transfected into SH-SY5Y cells respectively.Cell apoptosis was detected by flow cytometry,and cell proliferation was detected by MTT assay. Results The level of microRNA506 in brain tissue of cerebral ischemia reperfusion model mice was significantly higher than that of sham operation group((51.16±1.64)vs(12.82±1.66),P=0.008). The siRNA targeting microRNA506 significantly re-duced the growth of SH-SY5Y cells(P=0.0072),and induced the apoptosis of SH-SY5Y cells(P=0.0073). Transfection of microRNA506 enhanced the proliferation rate(P=0.020)of SH-SY5Y cells,and reduced the apoptosis of SH-SY5Y cells(P=0.017).Conclusions The expression level of microRNA506 in brain tissue of mice with cerebral ischemia reperfusion is increased.Overexpression of microRNA506 promotes the cell proliferation and decreases the apoptosis rate of SH-SY5Y cell while the low expression of microRNA506 de-creases the growth rate and induce cell apoptosis of SH-SY5Y cell.
ABSTRACT
Objective To investigate the effects of Atorvastatin on reducing the levels of inflammatory factors and on improving the quality of life in elderly patients with chronic kidney disease complicated with hyperlipidemia.Methods One hundred patients with chronic kidney disease accompanied with hyperlipidemia were enrolled from March 2016 to March 2017,and randomized into two groups:a control group undergoing conventional treatment with anticoagulant,diet control and standard glucocorticosteroid,and an observation group receiving Atorvastatin as add-on therapy to conventional treatment.Improvements of serum levels of inflammatory factors and blood lipid indices as well as total curative effect were compared between the two groups.Results The total effective rate was significantly higher in the observation group[94.0％ (47/50)]than in the control group (76.0％,38/50)(x2 =6.352,P＜0.05).After treatment,the improvements of blood lipid indices(TC,TG,LDL-C,HDL-C)were more in the observation group than in the control group(t =71.804,10.544,15.266,3.499,all P＜0.05).Before treatment,the serum levels of TNF-alpha,CRP and the 24h urine protein had no statistically significant differences between control and observation groups(P =0.406 or 0.678,respectively),but the levels in post-vs.pre-treatment were statistically significant lower in TNF-alpha[(1.1 ± 0.2) vs.(1.8 ± 0.3) μg/L],CRP [(8.2 ± 0.1) vs.(9.3 ± 0.1) mg/L] and 24h urine protein[(1.1±0.7)vs.(2.3±1.1)g/24 h](all P＜0.05).Conclusions Atorvastatin as add-on treatment to conventional therapy of chronic kidney diseases complicated with hyperlipidemia in the elderly has significant effects on controlling dyslipidemia and reducing inflammatory reactions so as to improve patients' quality of life.